Recently, the financing activity in the cell and gene therapy (CGT) sector has been steadily increasing. Seven related companies have completed financing in succession. According to incomplete statistics, the disclosed amount has exceeded 2 billion yuan. Among them, Weitao Biotechnology ranked first with an A+ round of over 50 million US dollars, and Xingrui Medicine ranked second with a B+ round of nearly 40 million US dollars. 

The business scope covers various specialized fields such as stem cells, CAR-T, and tumor immunology, featuring diversified technologies and a comprehensive coverage of the entire industrial chain. 

The influx of capital has accelerated, driving this sector into a new stage of rapid advancement where both technological iteration and industrialization implementation are advancing simultaneously.

Stem cell therapy

1、Weiqizhuo Biotechnology 

On April 27th, Shanghai Weizhi Zhuo Biotechnology Co., Ltd. completed a nearly 100 million yuan B++ round of financing. 

MicroZhuo Biotechnology was established in October 2015, specializing in cell therapy and regenerative medicine for severe liver diseases. The core product, HepaCure, a bio-artificial liver, has now entered the second phase of clinical research, being the fastest-developing product of its kind globally. Current clinical data shows that HepaCure demonstrates excellent safety and efficacy, significantly improving the survival rate of patients with liver failure, bringing new hope to the liver failure patient population.

2、Beisheng Hui Sheng 

On May 6th, Beishenghengsheng (Beijing) Biotechnology Co., Ltd. completed its A+ round of financing. 

Beishenghongsheng was established in September 2020, focusing on the fields of therapeutic reprogramming and regenerative medicine, and dedicated to developing iterative new cell therapies.

3、Iminokon 

On May 13th, Shanghai Iminocon Biotechnology Co., Ltd. completed a $250 million Series A financing round. 

Iminokon was established in December 2021, with the aim of applying gene editing technology to create a new antibody drug platform.

Immunotherapy

1、Renjing Biotechnology 

On April 21st, Renjing (Suzhou) Biotechnology Co., Ltd. completed a $200 million Series A financing round. 

Renjing Biotechnology was established in February 2021. It focuses on the research and development of mRNA (messenger ribonucleic acid) drugs and vaccines. Currently, it is concentrating on developing tumor therapeutic vaccines, tumor immunotherapy drugs and protein replacement products.

2、Weitao Biotechnology 

On April 28th, Weitao Biotechnology (Shanghai) Co., Ltd. completed an A+ round of financing of over 50 million US dollars. 

Weitao Biotech was established in June 2025. It was spun off from Beijing Shali Biomedical Co., Ltd., which has its leading in vivo CAR-T (in vivo CAR-T) technology platform. Weitao Biotech focuses on the research and development of in vivo CAR-T therapies based on the targeted lipid nanoparticle (LNP) delivery system, and is committed to providing breakthrough treatment solutions for hematological system tumors and autoimmune diseases.

3、Zhan'an Biotechnology 

On May 7th, Shenzhen Zai'an Biomedical Co., Ltd. completed a $38 million B-round financing. 

Zai'an Biotechnology was established in February 2022, focusing on novel immunotherapy. It independently developed the "Myeloid Engager Platform" technology platform and related original new drugs, aiming to enhance the comprehensive clinical benefits for a wide range of patients.

4、StarSharp Medicine 

On May 11th, Starbright Pharmaceuticals (Suzhou) Co., Ltd. completed a B+ round of financing worth nearly 40 million US dollars. 

Starbright Pharmaceuticals was established in August 2021. It has a rich pipeline in mRNA preventive vaccines, therapeutic tumor vaccines, and in vivo cell therapy (in vivo CAR-T), among which the respiratory syncytial virus vaccine (STR-V003) has obtained FDA clinical trial approval, and the tumor vaccine (STR-V005) and in vivo CAR-T technology (STR-P004) have successively entered the clinical trial stage.

Summary

As the understanding of cell characteristics and application mechanisms continues to deepen, the field of cell and gene therapy (CGT) is constantly witnessing innovative achievements, attracting numerous enterprises to increase their investment and efforts. 

Recently, 7 highly promising enterprises in this field have successfully obtained a new round of financing, which provides them with strong financial support to accelerate new drug research and clinical transformation. In the current era of rapid development of CGT technology, with the new round of financing, these enterprises are expected to overcome more traditional treatment challenges, develop more targeted and efficient personalized treatment plans, meet patients' urgent needs for improving quality of life and prolonging survival, further promote the wide application of CGT treatment technology in the medical field, and inject new vitality into the industry development.